Cardinal Health, Inc.

Hello, everyone. Thank you for joining us and welcome to Cardinal Health, Inc. fourth quarter fiscal year 2026 earnings release. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to David Frost, Vice President of Investor Relations. Please go ahead.

Good morning. Welcome to Cardinal Health's fourth quarter fiscal 2026 earnings conference call, and thank you for joining us. With me today are Cardinal Health CEO, Jason Hollar, and our CFO, Erin Ault. You can find this morning's earnings press release and investor presentation on the investor relations section of our website at ir.cardinalhealth.com. Since we will be making forward-looking statements today, let me remind you that the matters addressed in these statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a description of these risks and uncertainties. Please note that during our discussion today, the comments will be on a non-GAAP basis unless specifically called out as GAAP. Gap to non-gap reconciliations for all relevant periods can be found in the supporting schedules attached to our press release. For the Q&A portion of today's call, we kindly ask that you limit questions to one per participant so that we can try and give everyone an opportunity. With that, I will now turn the call over to Jason.

Good morning and thank you for joining us. We delivered a strong fourth quarter, concluding a fiscal 26 defined by consistent execution and broad-based performance across the enterprise. Our strategy remains clear and our relentless focus on execution is producing sustained operational momentum, positioning us for further value creation in fiscal 27 and beyond. Performance this quarter was once again led by pharmaceutical and specialty solutions, where resilient demand environment and continued strength across our specialty business, both upstream and downstream, drove strong results and extended the momentum we have built throughout fiscal 26. The global medical products and distribution segment demonstrated continued progress against our improvement plan initiatives, and we benefited from a non-recurring tailwind in the quarter. In Cardinal Health Brand, we again saw above-market growth when normalizing for the impact of the tariff refund. We were pleased with the performance of our other growth businesses, who again collectively delivered double-digit profit growth this quarter. This performance highlights the value of these specialized assets and their meaningful impact on enterprise results. We continue to experience a favorable demand environment and supportive secular health care trends across these businesses. Coupled with our strategic long-term investments, we see significant opportunities ahead. We enter fiscal 27 with momentum and a solid foundation for growth. Backed by the strength of a diversified portfolio, the resilience of our business model, and the dedication of our team, we are well positioned to continue delivering long-term value for our shareholders, customers, and the patients that they serve. I'll now turn the call over to Aaron to detail our financial results.